Bioiberica’s joint healthcare division and heparin business unit participated at the CPhl Russia fair, one of the most important events for the pharmaceutical sector
The Russian pharmaceutical market is growing at a 10 percent annual rate, and is expected to reach 25 Billion Dollars by 2018
Our company was granted “good” qualification within the A Group, the one formed by companies having their own manufacturing and R&D center in Spain
This certification is a recognition of the excellence standards achieved by Bioiberica in their effort to improve energy efficiencyDuring the next three years, our company has set the following objectives: 15% reduction in energy consumption per production unit, 10% of the energy will come from by-product use, and 5% from renewable energies
Bioiberica has been assigned to the A group, which corresponds to companies having their own R&D center and production plant, with a significant volume of research.The biotech company invests close to13% of its profits into R&D, and during 2013 they intend to begin marketing their personalized medicine range of products for osteoarthritis treatment.